Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

736 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Blastic transformation of BCR-ABL1 positive chronic myeloid leukaemia through acquisition of CBFB-MYH11 and mutant KIT.
Shoumariyeh K, Hussung S, Niemöller C, Bleul S, Veratti P, Follo M, Riba J, Philipp U, Palmer JM, Pfeifer D, Pantic M, Meggendorfer M, Hackanson B, Finke J, Haferlach T, Duyster J, Miething C, Becker H, von Bubnoff N. Shoumariyeh K, et al. Among authors: haferlach t. Br J Haematol. 2020 Sep;190(6):e339-e343. doi: 10.1111/bjh.16904. Epub 2020 Jun 24. Br J Haematol. 2020. PMID: 32579287 Free article. No abstract available.
Which compartments are involved in Philadelphia-chromosome positive chronic myeloid leukaemia? An answer at the single cell level by combining May-Grünwald-Giemsa staining and fluorescence in situ hybridization techniques.
Haferlach T, Winkemann M, Nickenig C, Meeder M, Ramm-Petersen L, Schoch R, Nickelsen M, Weber-Matthiesen K, Schlegelberger B, Schoch C, Gassmann W, Loffler H. Haferlach T, et al. Br J Haematol. 1997 Apr;97(1):99-106. doi: 10.1046/j.1365-2141.1997.9662656.x. Br J Haematol. 1997. PMID: 9136947 Free article.
RQ-PCR based WT1 expression in comparison to BCR-ABL quantification can predict Philadelphia negative clonal evolution in patients with imatinib-treated chronic myeloid leukaemia.
Schnittger S, Bacher U, Kern W, Tschulik C, Weiss T, Haferlach C, Haferlach T. Schnittger S, et al. Among authors: haferlach t, haferlach c. Br J Haematol. 2009 Sep;146(6):665-8. doi: 10.1111/j.1365-2141.2009.07812.x. Epub 2009 Jul 16. Br J Haematol. 2009. PMID: 19624538 Free article.
SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML).
Meggendorfer M, Roller A, Haferlach T, Eder C, Dicker F, Grossmann V, Kohlmann A, Alpermann T, Yoshida K, Ogawa S, Koeffler HP, Kern W, Haferlach C, Schnittger S. Meggendorfer M, et al. Among authors: haferlach t, haferlach c. Blood. 2012 Oct 11;120(15):3080-8. doi: 10.1182/blood-2012-01-404863. Epub 2012 Aug 23. Blood. 2012. PMID: 22919025 Free PMC article.
CEBPA double-mutated acute myeloid leukaemia harbours concomitant molecular mutations in 76·8% of cases with TET2 and GATA2 alterations impacting prognosis.
Grossmann V, Haferlach C, Nadarajah N, Fasan A, Weissmann S, Roller A, Eder C, Stopp E, Kern W, Haferlach T, Kohlmann A, Schnittger S. Grossmann V, et al. Among authors: haferlach t, haferlach c. Br J Haematol. 2013 Jun;161(5):649-658. doi: 10.1111/bjh.12297. Epub 2013 Mar 25. Br J Haematol. 2013. PMID: 23521373 Free article.
SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations.
Meggendorfer M, Bacher U, Alpermann T, Haferlach C, Kern W, Gambacorti-Passerini C, Haferlach T, Schnittger S. Meggendorfer M, et al. Among authors: haferlach t, haferlach c. Leukemia. 2013 Sep;27(9):1852-60. doi: 10.1038/leu.2013.133. Epub 2013 Apr 30. Leukemia. 2013. PMID: 23628959
736 results